3 completed, 3 unknown, 1 not yet recruiting, 1 recruiting. 4 Phase 2, 3 Phase 3, 2 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Unknown 1 |
| Phase 3 | 3 | Completed 1, Recruiting 1, Unknown 1 |
| Not applicable | 2 | Not yet recruiting 1, Unknown 1 |
Follow Progression Free Survival: new trials by email Literature Review of Progression Free Survival trials Research Report on Progression Free Survival
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sintilimab, Chidamide, and Azacitidine for Untreated Stage I-II Extranodal NK/T-Cell Lymphoma SCA Induction followed by Response-Adapted Therapy - Complete Remission Rateļ¼ CRR, Progression Free Survival | Not applicable | Not yet recruiting | Sun Yat-sen University | 30 | 2026-06-01 | 2026-04-21 |
| Survival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cancer Olanzapine 2.5 MG, Standard anti-tumor treatment, Nutritional advice - Advanced Cancer, Olanzapine | Phase 3 | Recruiting | Qinghai Red Cross Hospital | 230 | 2024-03-20 | 2024-03-29 |
| Id and Rd Maintenance Regimens After Induction of Remission in Multiple Myeloma. Ixazomib DX/Lenalidomide DX - Progression Free Survival, Overall Survival | Not applicable | Unknown | RenJi Hospital | 420 | 2023-02-16 | 2024-04-15 |
| IMPROVE Intervention Trial Implementing Non-invasive Circulating Tumor DNA Analysis to Optimize the Operative and Postoperative Treatment for Patients With Colorectal Cancer Capox (or FOLFOX) including flouropyrimidine and oxaliplatin combination chemotherapy, Intensified Follow-up Schedule - Colorectal Cancer, Circulating Tumor DNA | Phase 2 | Unknown | Karen-Lise Garm Spindler | 64 | 2018-10-01 | 2022-02-25 |
| A Study of Standard Treatment +/- Apatinib in Extensive Stage Small Cell Lung Cancer cisplatin, etoposide, cisplatin, etoposide, apatinib - Progression Free Survival | Phase 3 | Unknown | Qingdao University | 120 | 2017-03-01 | 2017-04-04 |
| Maintenance Therapy for Small-cell Lung Cancer cis Platinum, etoposide, S1 - Progression Free Survival | Phase 2 | Completed | Qingdao Central Hospital | 90 | 2017-01-01 | 2023-03-29 |
| Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer Osimertinib, docetaxel, bevacizumab - Progression Free Survival | Phase 2 / Phase 3 | Completed | Qingdao Central Hospital | 147 | 2015-08-01 | 2018-02-14 |
| Study of Target-Guided Chemotherapy in Metastatic Colorectal Patients Tailored Chemotherapy - Progression Free Survival | Phase 2 | Completed | Grupo Hospital de Madrid | 72 | 2009-10-01 | 2011-10-19 |
Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Lymphoma, Extranodal NK-T-Cell (1) · Multiple Myeloma (1)
Neoplasms (4) · Colonic Diseases (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Gastrointestinal Diseases (2) · Gastrointestinal Neoplasms (2) · Intestinal Diseases (2) · Intestinal Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Blood Protein Disorders (1) · Cardiovascular Diseases (1) · Colorectal Neoplasms (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1)
Cisplatin (2) · Etoposide (2) · Bevacizumab (1) · Docetaxel (1) · Olanzapine (1) · PE regimen (1) · S 1 (combination) (1) · apatinib (1) · osimertinib (1)
Qingdao Central Hospital (2) · Grupo Hospital de Madrid (1) · Karen-Lise Garm Spindler (1) · Qingdao University (1) · Qinghai Red Cross Hospital (1) · RenJi Hospital (1) · Sun Yat-sen University (1)
China (6) · Denmark (1) · Spain (1)
Antonio Cubillo, Md PhD (1) · Lu Zhong (1) · Zhuang Yu, MD, Ph. D (1)